You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (96) |
Back to Search
Safety and effectiveness of erenumab in chronic refractory migraine
- At: Virtual 2020 (2020)
- Type: Poster
- Poster code: POS-HPS-003
- By: ALONSO PERALTA, Carlos Angel (Hospital Universitario Marqués de Valdecilla, Hospital pharmacy, Spain)
- Co-author(s): Maria Rioja Carrera: Hospital pharmacy, Hospital Universitario Marqués de valdecilla, Santander, Spain
Julia Sánchez Gundín: Hospital pharmacy, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Berta Rogado Vegas: Hospital pharmacy, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Carlos Angel Alonso Peralta: Hospital pharmacy, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Paula del Rio Ortega: Hospital pharmacy, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Juan Casanova Vázquez: Hospital pharmacy, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Marta Valero Dominguéz: Hospital pharmacy, Hospital Universitario Marqués de Valdecilla, Santander, Spain - Abstract:
Background
Erenumab is a human monoclonal antibody that inhibits the peptide receptor related to the calcitonin gene, a vasodilator associated with the physiopathology of migraine.Purpose
To evaluate the effectiveness and safety of erenumab in chronic migraine of ≥8 days/month, with previous failure to 3 or more drugs, including botulinum toxin.
Me..
The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026